Resources

Client Alerts, News Articles, Blog Posts, & Multimedia

Everything you need to know about BMD and the industry.

Returning to Work: Forecasting the New Normal in Business

Client Alert

We cannot predict when businesses will reopen across the country. As we publish this Alert, dynamic business leaders are cooperating in comprehensive efforts to create safe work environments so that they can all re-engage the workforce.

However, we can predict the new normal in business. Some important studies were published yesterday, and the new normal in business will be facemasks for all employees, and probably all business visitors.

The scientists at the National Institutes of Health published a study yesterday in the New England Journal of Medicine addressing the question of whether the coronavirus can be “aerosolized” when people are speaking. The study advises that the coronavirus can be aerosolized and transmitted between individuals who speak in-person.

In an accompanying commentary to the study, a Harvard University biologist remarked that those aerosols from infected persons may pose a threat, “even at considerable distances and in enclosed spaces,” and identified the wearing of a masks as a prophylactic measure.

Additionally, Nature Medicine published its study yesterday finding that individuals may be infectious for two to three days before showing symptoms of Covid-19.    

What does this mean for employers?

Start sourcing facemasks now. Whether essential or non-essential, healthcare or non-healthcare, all employers will need to have facemasks for employees, and probably visitors, in order to return to new normal operations.  

When combining the studies and the commentary, it makes the current preventative measures (six-foot rule, temperature at door, sending sick employees home, etc.) look less effective than believed. Speaking can be as dangerous as coughs and sneezes. Either by governmental order, regulatory requirement, or to avoid novel claims by employees, employers will need to provide facemasks. 

We expect that additional requirements will also be issued before businesses will reopen, so it probably makes sense to start sourcing disinfectant products at the same time.

For additional information, please contact Jeffrey C. Miller, jcmiller@bmdllc.com or 216.658.2323, or any member of the L+E Team at BMD


USCIS Policy Change Impacting Work Authorization: Advisory for Employers and Human Resources

USCIS has issued a policy memorandum pausing immigration benefit processing for individuals from 19 high-risk countries and requiring a re-review of certain previously approved cases. This change may affect work authorization, employment verification, and workforce stability. Employers and HR teams should review impacted employees and update compliance procedures.

CMS Releases CY 2026 Medicare Physician Fee Schedule Final Rule with Key Payment and Telehealth Updates

CMS issued the CY 2026 Medicare Physician Fee Schedule Final Rule on October 31, 2025, with changes effective January 1, 2026. The Final Rule includes increases to the conversion factor, a new efficiency adjustment, updates to practice expense methodology, permanent telehealth policy changes, revised payment for skin substitutes, expanded rules for Part B drugs and biologicals, enhanced policies for Rural Health Clinics and Federally Qualified Health Centers, and new care management and behavioral health services.

Ohio Department of Medicaid Updates: Key Changes to Physician Reimbursement Rates in Early Parenthood

The Ohio Department of Medicaid has proposed amending Ohio Administrative Code Rule related to covered Medicaid reimbursements for physicians. Beginning on January 1, 2026, they are proposing an increase to rates for prenatal care, childbirth, and infant care and provider visits.

Name, Image, and Likeness Agreements in Healthcare

For example, some healthcare providers have begun to utilize "Name, Image, and Likeness" agreements to promote the brand they have created through their healthcare practice.  We have seen the most healthcare NIL activity with longevity and wellness providers, as well as orthopedics.

Compounding GLP-1 Drugs - Recent Updates

Recent guidance from the Ohio Board of Pharmacy (“BOP”) indicates that providers should generally use the FDA approved GLP-1 drug, rather than a non-FDA approved compounded version of the medication. Importantly, if a GLP-1 drug is commercially available, it cannot be copied through compounding. Currently, compounded copies of Tirzepatide and Semaglutide are not permitted.